In situ ハイブリダイゼーション（ISH）市場 – 2030年までの世界予測

本調査レポートでは、In situ ハイブリダイゼーション（ISH）市場を、提供内容（消耗品（キットおよび試薬、プローブおよびプローブキット、付属品およびその他の消耗品）、機器、サービスおよびソフトウェア）、技術（蛍光in situ ハイブリダイゼーション（DNA蛍光 in situ ハイブリダイゼーション、RNA蛍光in situ ハイブリダイゼーション、PNA蛍光 in situ ハイブリダイゼーション）、発色 in situ ハイブリダイゼーション）、用途（臨床診断（がん診断、遺伝性疾患検出、感染症診断など）、研究用途（神経科学、免疫学など）、創薬および開発）、エンドユーザー（病院および診断ラボ、学術研究機関、製薬およびバイオテクノロジー企業、受託研究機関）および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。本レポートは、in situ ハイブリダイゼーション市場の成長に影響を与える重要な要素（牽引要因、傾向、課題、機会など）に関する詳細な情報を提供します。主要業界プレーヤーを徹底的に分析し、各社の事業概要、製品／サービス、主要戦略、協業、パートナーシップ、契約に関する洞察を提供しています。さらに、本レポートでは、in situ ハイブリダイゼーション市場における新製品の発売や買収といった最近の動向も網羅しています。

The in situ hybridization market is expected to reach USD 2.35 billion in 2030 from USD 1.64 billion in 2025, at a CAGR of 7.4% during the forecast period. The expansion of the in situ hybridization (ISH) market is largely driven by continuous technological advancements within ISH platforms. Innovations such as enhanced probe designs, automation, and multiplexing capabilities have markedly improved assay sensitivity, specificity, and throughput. These enhancements align with the increasing need for precision medicine and the development of laboratory-developed tests (LDTs). Such advancements facilitate the identification of patient-specific genetic markers, solidifying ISH’s role as a critical component in personalized treatment approaches. Furthermore, the emerging field of spatial transcriptomics within cancer and neuroscience research underscores the necessity for highly sensitive and multiplexed ISH technologies to analyze gene expression in its tissue context. This demand is propelling ongoing innovation in the ISH sector. Notably, ISH presents distinct advantages over immunohistochemistry (IHC), particularly with its ability to detect direct nucleic acid, which enhances diagnostic accuracy and disease characterization, further contributing to the market’s growth.

In situ ハイブリダイゼーション（ISH）市場は、2025年の16億4,000万米ドルから2030年には23億5,000万米ドルに達し、予測期間中に7.4%のCAGRで成長すると予想されています。In situ ハイブリダイゼーション（ISH）市場の拡大は、ISHプラットフォームにおける継続的な技術進歩によって大きく推進されています。プローブ設計、自動化、マルチプレックス化機能の向上といったイノベーションにより、アッセイの感度、特異性、スループットが著しく向上しています。これらの機能強化は、高精度医療へのニーズの高まりや、ラボ開発検査（LDT）の開発と整合しています。こうした進歩により、患者固有の遺伝子マーカーの特定が容易になり、個別化治療アプローチにおけるISHの重要な要素としての地位が確固たるものになっています。さらに、がんや神経科学研究における空間トランスクリプトミクスという新たな分野が台頭し、組織の状況に応じた遺伝子発現を解析するための高感度かつマルチプレックス化されたISH技術の必要性が浮き彫りになっています。こうした需要が、ISH分野における継続的なイノベーションを推進しています。特に、ISH は免疫組織化学 (IHC) に比べて明確な利点があり、特に核酸を直接検出する能力により診断の精度と疾患の特徴付けが向上し、市場の成長にさらに貢献しています。

“The fluorescent in situ hybridization technology segment accounted for the largest technology market share in 2024.”

The in situ hybridization market by technology is segmented into fluorescent in situ hybridization and chromogenic in situ hybridization. The fluorescent in situ hybridization technology is further segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, and PNA fluorescent in situ hybridization. In 2024, the fluorescent in situ hybridization technology segment accounted for the largest market share, by technology. The dominant position of this technology segment is attributable to its exceptional sensitivity, specificity, and versatility in detecting genetic anomalies at both DNA and RNA levels. Fluorescence In Situ Hybridization (FISH) provides high-resolution insights for identifying chromosomal rearrangements, gene amplifications, and deletions, making it indispensable in cancer diagnostics, the identification of genetic disorders, and prenatal screenings. FISH enables concurrent detection of multiple targets through the use of various fluorescent probes, catering to both clinical and research needs. Furthermore, the extensive incorporation of FISH in personalized medicine, particularly for HER2 and ALK assessments in oncology, has significantly bolstered its demand in recent years.

“Consumables segment is projected to register the highest CAGR in the global in situ hybridization market during the forecast period.”

By offering, the in situ hybridization market is segmented into consumables, instruments, services & software. The consumables segment is further sub-segmented into kits & reagents, probes & probe kits, and accessories & other consumables. The consumables segment is expected to register the highest growth rate during the forecast period. The expansion of the market for consumables in in situ hybridization (ISH) procedures is fundamentally linked to their increasing application in cancer diagnostics and various other disease areas. This uptick in utilization directly correlates with a heightened demand for essential consumables, including probes and probe kits, integral to every ISH assay. As testing volumes escalate in both clinical and research environments, the demand for these materials is poised for steady growth. Furthermore, the ongoing development and approval of advanced ISH-based diagnostic tests, such as Roche’s VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, are anticipated to further broaden the consumables market. Such innovations enhance the accuracy and specificity of diagnostics for conditions such as B-cell malignancies, thereby incentivizing laboratories and healthcare facilities to increasingly incorporate ISH methodologies into their testing repertoire. This upward trajectory in clinical uptake will consistently drive the demand for corresponding consumables, underpinning robust growth in this segment. Additionally, it presents significant opportunities for key industry players to fortify their market presence through innovative product development and strategic supply chain enhancements.

“The Asia Pacific region is growing at the highest CAGR in the in situ hybridization market during the study period.”

The Asia Pacific region is anticipated to experience the highest growth rate in the in situ hybridization (ISH) market throughout the forecast period. This growth is driven by significant advancements in healthcare infrastructure and heightened investments in molecular diagnostics and precision medicine from both government entities and private sector stakeholders. Key nations, including China, India, Japan, and South Korea, are actively advancing research initiatives in genomics and personalized medicine through targeted national programs and funding mechanisms. Concurrently, the increasing prevalence of chronic diseases—such as cancer, infectious diseases, and genetic disorders—is propelling the demand for sophisticated diagnostic technologies like ISH. The burgeoning presence of regional diagnostic firms, coupled with strategic partnerships with global entities, is further facilitating market access and enhancing technology adoption.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
• By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Bio-Techne. (US), and Biocare Medical (US) are some of the key players in the in situ hybridization market.

The study includes an in-depth competitive analysis of these key players in the in situ hybridization market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the in situ hybridization market by offering (consumables (kits & reagents, probes & probe kits, accessories & other consumables), instruments, services & software), technology (fluorescent in situ hybridization (DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization), chromogenic in situ hybridization), application (clinical diagnostics (cancer diagnostics, genetic disorder detection, infectious disease diagnostics, and others), research applications (neuroscience, immunology, others), drug discovery & development), end user (hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the in situ hybridization market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments, such as new product launches and acquisitions within the in situ hybridization market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall in situ hybridization market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers [technological advancements enhancing in situ hybridization capabilities, increasing adoption of in situ hybridization in precision medicine and laboratory-developed tests (LDTs), rising demand for spatial transcriptomics in cancer and neuroscience research, expansion of multiplex in situ hybridization techniques for multi-gene detection], restraints [high costs of in situ hybridization techniques, competition from alternative molecular diagnostic techniques (qPCR, NGS)], opportunities [advantages over other techniques such as immunohistochemistry (IHC), expansion in emerging markets, growing adoption of companion diagnostics (CDx) solutions], and challenges [technical complexities associated with in situ hybridization].
• Product Development/Innovation: Detailed insights on newly launched and approved products/services of the in situ hybridization market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the in situ hybridization market
• Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Bioview (Isreal), NEOGENOMICS LABORATORIES (US), Qiagen (Netherlands), Bio-Techne. (US) and Biocare Medical (US), among others, in the in situ hybridization market.

Table of Contents

1               INTRODUCTION              40

1.1           STUDY OBJECTIVES       40

1.2           MARKET DEFINITION   40

1.3           STUDY SCOPE   41

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 41

1.3.2        INCLUSIONS & EXCLUSIONS       42

1.3.3        YEARS CONSIDERED      43

1.3.4        CURRENCY CONSIDERED            43

1.4           STAKEHOLDERS               43

1.5           SUMMARY OF CHANGES               44

2               RESEARCH METHODOLOGY       45

2.1           RESEARCH DATA              45

2.1.1        SECONDARY DATA          46

2.1.1.1    Key sources of secondary data            46

2.1.1.2    Key objectives of secondary research                 46

2.1.2        PRIMARY DATA 47

2.1.2.1    Breakdown of primaries      47

2.1.2.2    Key objectives of primary research    47

2.2           MARKET ESTIMATION METHODOLOGY               48

2.2.1        GLOBAL MARKET SIZE ESTIMATION      48

2.2.2        SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)       51

2.3           MARKET GROWTH RATE FORECAST       53

2.4           DATA TRIANGULATION                55

2.5           STUDY ASSUMPTIONS  56

2.6           RESEARCH LIMITATIONS             56

2.7           RISK ANALYSIS  57

3               EXECUTIVE SUMMARY  58

4               PREMIUM INSIGHTS       63

4.1           IN SITU HYBRIDIZATION MARKET OVERVIEW   63

4.2           NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING AND COUNTRY    64

4.3           IN SITU HYBRIDIZATION MARKET SHARE, BY END USER, 2024        65

4.4           IN SITU HYBRIDIZATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         66

5               MARKET OVERVIEW       67

5.1           INTRODUCTION              67

5.2           MARKET DYNAMICS       67

5.2.1        DRIVERS               68

5.2.1.1    Technological innovations for advanced in situ hybridization capabilities             68

5.2.1.2    Increasing adoption of in situ hybridization in precision medicines and laboratory-developed tests        69

5.2.1.3    Rising demand for spatial transcriptomics in cancer and neuroscience research          70

5.2.2        RESTRAINTS      70

5.2.2.1    Competition from alternative molecular diagnostic techniques                 70

5.2.2.2    High cost of in situ hybridization techniques in research and clinical applications              70

5.2.3        OPPORTUNITIES              71

5.2.3.1    Advantages of in situ hybridization over competing technologies                 71

5.2.3.2    Rising adoption of companion diagnostic solutions        71

5.2.3.3    High growth opportunities in emerging economies        72

5.2.4        CHALLENGES    72

5.2.4.1    Technical complexities associated with in situ hybridization                 72

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            73

5.4           VALUE CHAIN ANALYSIS               73

5.5           ECOSYSTEM ANALYSIS  75

5.5.1        ROLE IN ECOSYSTEM     76

5.6           TECHNOLOGY ANALYSIS             78

5.6.1        KEY TECHNOLOGIES     78

5.6.1.1    Fluorescence In Situ Hybridization (FISH)     78

5.6.1.2    Chromogenic In Situ Hybridization (CISH)    78

5.6.1.3    RNAscope              78

5.6.2        COMPLEMENTARY TECHNOLOGIES       79

5.6.2.1    Immunofluorescence (IF)   79

5.6.2.2    Next-generation Sequencing (NGS) 79

5.6.3        ADJACENT TECHNOLOGIES       79

5.6.3.1    Immunohistochemistry (IHC)            79

5.7           PATENT ANALYSIS          80

5.7.1        TOP APPLICANTS/OWNERS (COMPANIES) FOR IN SITU HYBRIDIZATION PATENTS          80

5.7.2        LIST OF KEY PATENTS   81

5.8           KEY CONFERENCES & EVENTS, 2025–2026              82

5.9           PORTER’S FIVE FORCES ANALYSIS           83

5.9.1        INTENSITY OF COMPETITIVE RIVALRY 84

5.9.2        THREAT OF SUBSTITUTES          85

5.9.3        BARGAINING POWER OF BUYERS             85

5.9.4        BARGAINING POWER OF SUPPLIERS       85

5.9.5        THREAT OF NEW ENTRANTS      85

5.10         KEY STAKEHOLDERS & BUYING CRITERIA            86

5.10.1      KEY STAKEHOLDERS IN BUYING PROCESS           86

5.10.2      KEY BUYING CRITERIA  87

5.11         PRICING ANALYSIS          89

5.11.1      AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION PRODUCTS,

BY KEY PLAYER, 2022–2024            89

5.11.2      AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION CONSUMABLES, BY REGION, 2022–2024                 91

5.12         INVESTMENT & FUNDING SCENARIO     91

5.13         REGULATORY LANDSCAPE         92

5.13.1      REGULATORY FRAMEWORK       92

5.13.1.1  North America      92

5.13.1.2  Europe   92

5.13.1.3  Asia Pacific            93

5.13.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             93

5.14         IMPACT OF AI/GEN AI ON IN SITU HYBRIDIZATION MARKET               95

5.14.1      KEY USE CASES 95

5.14.2      IMPACT OF AI ON IN SITU HYBRIDIZATION ECOSYSTEM                 96

5.14.3      FUTURE OF AI IN IN SITU HYBRIDIZATION ECOSYSTEM                 97

5.15         IMPACT OF 2025 US TARIFF ON IN SITU HYBRIDIZATION MARKET               97

5.15.1      INTRODUCTION              97

5.15.2      KEY TARIFF RATES          98

5.15.3      PRICE IMPACT ANALYSIS             100

5.15.4      IMPACT ON COUNTRY/REGION                100

5.15.4.1  North America      100

5.15.4.1.1                US           100

5.15.4.2  Europe   101

5.15.4.3  Asia Pacific            101

5.15.5      IMPACT ON END-USE INDUSTRIES          102

5.15.5.1  Hospitals & diagnostic laboratories   102

5.15.5.2  Academic & research institutes          103

5.15.5.3  Pharmaceutical & biotechnology companies    103

5.15.5.4  Contract research organizations         103

6               IN SITU HYBRIDIZATION MARKET, BY OFFERING                 104

6.1           INTRODUCTION              105

6.2           CONSUMABLES 105

6.2.1        KITS & REAGENTS            109

6.2.1.1    Increasing demand for companion diagnostics and personalized medicines to support market growth 109

6.2.2        PROBE & PROBE KITS    113

6.2.2.1    Technological advancements in probe design and chemistry to propel market growth           113

6.2.3        ACCESSORIES & OTHER CONSUMABLES                117

6.2.3.1    Growing adoption of in situ hybridization in research and clinical diagnostics to aid market growth       117

6.3           INSTRUMENTS 120

6.3.1        AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS                 123

6.3.1.1    Increased adoption of faster and more reliable automated systems to boost market growth        123

6.3.2        MANUAL IN SITU HYBRIDIZATION INSTRUMENTS                 127

6.3.2.1    Persistent demand in emerging economies to maintain market growth    127

6.4           SOFTWARE         130

6.4.1        INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SOFTWARE TO SUPPORT GROWTH                 130

6.5           SERVICES             134

6.5.1        DATA INTERPRETATION SERVICES         137

6.5.1.1    Increasing use of multiplex assays and spatial biology techniques to boost segment growth     137

6.5.2        CUSTOM PROBE DESIGN SERVICES         141

6.5.2.1    Rising demand for customized probes in research and drug development to favor market growth 141

7               IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY                 145

7.1           INTRODUCTION              146

7.2           FLUORESCENCE IN SITU HYBRIDIZATION (FISH)                 146

7.2.1        DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH)     150

7.2.1.1    Extensive use in research and companion diagnostics to fuel segment growth    150

7.2.2        RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH)     154

7.2.2.1    Rise in biomedical research activity to drive adoption of RNA-FISH technology   154

7.2.3        PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH)     157

7.2.3.1    High sensitivity offered by PNA FISH to fuel precise and reliable detection at low probe concentrations               157

7.3           CHROMOGENIC IN SITU HYBRIDIZATION (CISH)                 161

7.3.1        COST-EFFECTIVENESS, PRESERVATION OF TISSUE MORPHOLOGY, AND EASE OF INTERPRETATION TO BOOST SEGMENT GROWTH       161

8               IN SITU HYBRIDIZATION MARKET, BY APPLICATION                 165

8.1           INTRODUCTION              166

8.2           CLINICAL DIAGNOSTIC APPLICATIONS 166

8.2.1        CANCER DIAGNOSTICS 170

8.2.1.1    Rising number of cancer cases and increasing focus on precision medicines to drive segment 170

8.2.2        INFECTIOUS DISEASE DIAGNOSTICS      174

8.2.2.1    Growing demand for high sensitivity and specificity diagnostic methods in resource-limited settings to spur market growth        174

8.2.3        GENETIC DISEASE DIAGNOSTICS             177

8.2.3.1    Rising adoption of prenatal and neonatal screening to propel segment growth    177

8.2.4        OTHER CLINICAL DIAGNOSTIC APPLICATIONS 181

8.3           RESEARCH APPLICATIONS          184

8.3.1        NEUROSCIENCE RESEARCH        187

8.3.1.1    Growing focus on neurological research to increase R&D in neuroscience-based ISH technologies               187

8.3.2        IMMUNOLOGY RESEARCH           191

8.3.2.1    Rising prevalence of autoimmune diseases to support market growth    191

8.3.3        OTHER RESEARCH APPLICATIONS          194

8.4           DRUG DISCOVERY & DEVELOPMENT     198

8.4.1        RISING DEMAND FOR NUCLEIC ACID-BASED THERAPIES TO FAVOR MARKET GROWTH           198

9               IN SITU HYBRIDIZATION MARKET, BY END USER                 202

9.1           INTRODUCTION              203

9.2           HOSPITALS & DIAGNOSTIC LABORATORIES       203

9.2.1        RISING DEMAND FOR MOLECULAR TESTS AND INCREASING NEED FOR ACCURATE DISEASE DIAGNOSIS TO DRIVE MARKET 203

9.3           ACADEMIC & RESEARCH INSTITUTES    207

9.3.1        INCREASING GOVERNMENT AND PRIVATE FUNDING FOR LIFE SCIENCE AND BIOMEDICAL RESEARCH TO FUEL MARKET GROWTH          207

9.4           PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 210

9.4.1        INCREASING FOCUS ON DEVELOPING PRECISION TREATMENTS TO PROPEL MARKET GROWTH   210

9.5           CONTRACT RESEARCH ORGANIZATIONS             213

9.5.1        INCREASING OUTSOURCING OF RESEARCH ACTIVITIES IN TISSUE DIAGNOSTICS TO SUPPORT MARKET GROWTH                 213

10            IN SITU HYBRIDIZATION MARKET, BY REGION 217

10.1         INTRODUCTION              218

10.2         NORTH AMERICA             218

10.2.1      MACROECONOMIC ANALYSIS FOR NORTH AMERICA                 219

10.2.2      US           225

10.2.2.1  US to dominate North American in situ hybridization market during study period              225

10.2.3      CANADA               230

10.2.3.1  Increasing cancer burden and expanding in situ hybridization applications in cancer research to propel market growth               230

10.3         EUROPE               235

10.3.1      MACROECONOMIC ANALYSIS FOR EUROPE        235

10.3.2      GERMANY           241

10.3.2.1  Research advancements and corporate developments to fuel market growth       241

10.3.3      UK          246

10.3.3.1  High government healthcare investments in genomic research to support market growth        246

10.3.4      FRANCE                250

10.3.4.1  Rising government investment in pharmaceutical industry to propel market growth           250

10.3.5      ITALY    255

10.3.5.1  High R&D investments and advanced pharmaceutical industry to favor market growth             255

10.3.6      SPAIN    260

10.3.6.1  Growing focus on cancer biomarker development to aid market growth    260

10.3.7      REST OF EUROPE             264

10.4         ASIA PACIFIC     269

10.4.1      MACROECONOMIC ANALYSIS FOR ASIA PACIFIC                 270

10.4.2      CHINA  276

10.4.2.1  Increased focus on precision medicine and local manufacturing of in situ hybridization technologies to spur market growth          276

10.4.3      JAPAN   280

10.4.3.1  Stringent regulatory guidelines and large geriatric population to augment market growth      280

10.4.4      INDIA    285

10.4.4.1  Rising awareness of cancer and genetic disorders to support market growth       285

10.4.5      AUSTRALIA         290

10.4.5.1  Robust government support and active genetic research to propel market growth       290

10.4.6      SOUTH KOREA  295

10.4.6.1  Increased focus on genomic and diagnostic research to aid market adoption of in situ hybridization products       295

10.4.7      REST OF ASIA PACIFIC   300

10.5         LATIN AMERICA                305

10.5.1      MACROECONOMIC ANALYSIS FOR LATIN AMERICA                 305

10.5.2      BRAZIL 311

10.5.2.1  Growing focus on precision diagnostics to drive market                 311

10.5.3      MEXICO                316

10.5.3.1  Increasing collaboration among key players to spur market growth    316

10.5.4      REST OF LATIN AMERICA             320

10.6         MIDDLE EAST   325

10.6.1      MACROECONOMIC ANALYSIS FOR MIDDLE EAST                 325

10.6.2      GCC COUNTRIES              331

10.6.2.1  Kingdom of Saudi Arabia    335

10.6.2.1.1                Expanding role of in situ hybridization products in research and clinical practice to boost market growth    335

10.6.2.2  UAE        340

10.6.2.2.1                Rising government support and incorporation of in situ hybridization technologies by hospitals to aid market growth       340

10.6.3      REST OF GCC COUNTRIES           345

10.6.4      REST OF MIDDLE EAST 350

10.7         AFRICA 355

10.7.1      GROWING DEMAND FOR GENOMICS INFRASTRUCTURE AND MOLECULAR DIAGNOSTICS TO PROPEL MARKET GROWTH             355

10.7.2      MACROECONOMIC ANALYSIS FOR AFRICA          355

11            COMPETITIVE LANDSCAPE         361

11.1         INTRODUCTION              361

11.2         KEY PLAYERS STRATEGIES/RIGHT TO WIN          361

11.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET     361

11.3         REVENUE ANALYSIS, 2020–2024  363

11.4         MARKET SHARE ANALYSIS, 2024                 364

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 367

11.5.1      STARS   367

11.5.2      EMERGING LEADERS     367

11.5.3      PERVASIVE PLAYERS      367

11.5.4      PARTICIPANTS 367

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         369

11.5.5.1  Company footprint               369

11.5.5.2  Region Footprint  370

11.5.5.3  Offering footprint 371

11.5.5.4  Technology footprint           372

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        373

11.6.1      PROGRESSIVE COMPANIES         373

11.6.2      RESPONSIVE COMPANIES            373

11.6.3      DYNAMIC COMPANIES  373

11.6.4      STARTING BLOCKS         373

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 375

11.6.5.1  Detailed list of key startups/SMEs    375

11.6.5.2  Competitive benchmarking of key startups/SMEs          376

11.7         COMPANY VALUATION & FINANCIAL METRICS 377

11.7.1      FINANCIAL METRICS      377

11.7.2      COMPANY VALUATION 377

11.8         BRAND/PRODUCT COMPARISON             378

11.9         COMPETITIVE SCENARIO             379

11.9.1      PRODUCT LAUNCHES & APPROVALS     379

11.9.2      DEALS  380

12            COMPANY PROFILES      381

12.1         KEY PLAYERS     381

12.1.1      F. HOFFMANN-LA ROCHE LTD. 381

12.1.1.1  Business overview 381

12.1.1.2  Products/Services/Solutions offered 382

12.1.1.3  Recent developments           384

12.1.1.3.1                Product launches & approvals            384

12.1.1.4  MnM view              385

12.1.1.4.1                Right to win           385

12.1.1.4.2                Strategic choices   385

12.1.1.4.3                Weaknesses & competitive threats     385

12.1.2      DANAHER            386

12.1.2.1  Business overview 386

12.1.2.2  Products/Services/Solutions offered 387

12.1.2.3  Recent developments           389

12.1.2.3.1                Product launches  389

12.1.2.3.2                Deals      390

12.1.2.4  MnM view              390

12.1.2.4.1                Right to win           390

12.1.2.4.2                Strategic choices   391

12.1.2.4.3                Weaknesses & competitive threats     391

12.1.3      ABBOTT               392

12.1.3.1  Business overview 392

12.1.3.2  Products/Services/Solutions offered 393

12.1.3.3  MnM view              398

12.1.3.3.1                Right to win           398

12.1.3.3.2                Strategic choices   398

12.1.3.3.3                Weaknesses & competitive threats     398

12.1.4      THERMO FISHER SCIENTIFIC INC.            399

12.1.4.1  Business overview 399

12.1.4.2  Products/Services/Solutions offered 400

12.1.4.3  MnM view              401

12.1.4.3.1                Right to win           401

12.1.4.3.2                Strategic choices   401

12.1.4.3.3                Weaknesses & competitive threats     401

12.1.5      BIO-TECHNE     402

12.1.5.1  Business overview 402

12.1.5.2  Products/Services/Solutions offered 403

12.1.5.3  Recent developments           405

12.1.5.3.1                Product launches  405

12.1.5.3.2                Deals      406

12.1.5.4  MnM view              406

12.1.5.4.1                Right to win           406

12.1.5.4.2                Strategic choices   406

12.1.5.4.3                Weaknesses & competitive threats     407

12.1.6      AGILENT TECHNOLOGIES, INC.                408

12.1.6.1  Business overview 408

12.1.6.2  Products/Services/Solutions offered 409

12.1.7      QIAGEN                412

12.1.7.1  Business overview 412

12.1.7.2  Products/Services/Solutions offered 414

12.1.8      BIOCARE MEDICAL, LLC                415

12.1.8.1  Business overview 415

12.1.8.2  Products/Services/Solutions offered 415

12.1.8.3  Recent developments           419

12.1.8.3.1                Deals      419

12.1.9      BIOVIEW              421

12.1.9.1  Business overview 421

12.1.9.2  Products/Services/Solutions offered 421

12.1.10   CREATIVE BIOARRAY     422

12.1.10.1                 Business overview 422

12.1.10.2                 Products/Services/Solutions offered 422

12.1.11   ABNOVA CORPORATION              425

12.1.11.1                 Business overview 425

12.1.11.2                 Products/Services/Solutions offered 425

12.1.12   ZYTOMICS          427

12.1.12.1                 Business overview 427

12.1.12.2                 Products/Services/Solutions offered 427

12.1.13   ENZO BIOCHEM INC.     431

12.1.13.1                 Business overview 431

12.1.13.2                 Products/Services/Solutions offered 432

12.1.13.3                 Recent developments           434

12.1.13.3.1             Product launches  434

12.1.14   CYTOTEST INC.                 435

12.1.14.1                 Business overview 435

12.1.14.2                 Products/Services/Solutions offered 435

12.1.15   GENEMED BIOTECHNOLOGIES, INC.      438

12.1.15.1                 Business overview 438

12.1.15.2                 Products/Services/Solutions offered 438

12.2         OTHER PLAYERS              440

12.2.1      MOLECULAR INSTRUMENTS, INC.            440

12.2.2      OXFORD GENE TECHNOLOGY IP LIMITED          441

12.2.3      HISTO-LINE LABORATORIES      442

12.2.4      METASYSTEMS 443

12.2.5      BIOGENEX          445

12.2.6      LGC BIOSEARCH TECHNOLOGIES            446

12.2.7      BIODISCOVERY LLC        447

12.2.8      KANEKA EUROGENTEC S.A.        448

12.2.9      LIFE TECHNOLOGIES (INDIA) PVT. LTD.               449

12.2.10   GENECOPOEIA, INC.       450

13            APPENDIX           452

13.1         DISCUSSION GUIDE        452

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                456

13.3         CUSTOMIZATION OPTIONS        458

13.4         RELATED REPORTS         458

13.5         AUTHOR DETAILS           459

LIST OF TABLES

TABLE 1                IN SITU HYBRIDIZATION MARKET: INCLUSIONS & EXCLUSIONS 42

TABLE 2                IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS     54

TABLE 3                IN SITU HYBRIDIZATION MARKET: RISK ANALYSIS            57

TABLE 4                IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    68

TABLE 5                IN SITU HYBRIDIZATION MARKET: ROLE IN ECOSYSTEM       76

TABLE 6                IN SITU HYBRIDIZATION MARKET: DETAILED ANALYSIS OF KEY PATENTS, 2024              81

TABLE 7                IN SITU HYBRIDIZATION MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026                82

TABLE 8                IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES      83

TABLE 9                INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION-BASED OFFERINGS        86

TABLE 10              KEY BUYING CRITERIA, BY END USER    88

TABLE 11              AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION PRODUCTS,

BY KEY PLAYER, 2022–2024 (USD)              89

TABLE 12              AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION CONSUMABLES,

BY REGION, 2022–2024 (USD)      91

TABLE 13              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 93

TABLE 14              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           94

TABLE 15              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 94

TABLE 16              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 95

TABLE 17              US ADJUSTED RECIPROCAL TARIFF RATES                 98

TABLE 18              IN SITU HYBRIDIZATION PRODUCTS-RELATED TARIFF REVISION             99

TABLE 19              IMPACT ON END-USE APPLICATIONS OF IN SITU HYBRIDIZATION PRODUCTS           102

TABLE 20              IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION)     105

TABLE 21              IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY REGION,

2023–2030 (USD MILLION)            106

TABLE 22              NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            106

TABLE 23              EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            107

TABLE 24              ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            107

TABLE 25              LATIN AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            108

TABLE 26              MIDDLE EAST: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)                 108

TABLE 27              GCC COUNTRIES: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            108

TABLE 28              IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            109

TABLE 29              KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)       110

TABLE 30              NORTH AMERICA: KITS & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            110

TABLE 31              EUROPE: KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     111

TABLE 32              ASIA PACIFIC: KITS & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            111

TABLE 33              LATIN AMERICA: KITS & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            112

TABLE 34              MIDDLE EAST: KITS & REAGENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            112

TABLE 35              GCC COUNTRIES: KITS & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            112

TABLE 36              PROBE & PROBE KITS MARKET, BY REGION, 2023–2030 (USD MILLION)            114

TABLE 37              NORTH AMERICA: PROBE & PROBE KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            114

TABLE 38              EUROPE: PROBE & PROBE KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            115

TABLE 39              ASIA PACIFIC: PROBE & PROBE KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            115

TABLE 40             LATIN AMERICA: PROBE & PROBE KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            116

TABLE 41              MIDDLE EAST: PROBE & PROBE KITS MARKET, BY REGION,

2023–2030 (USD MILLION)            116

TABLE 42              GCC COUNTRIES: PROBE & PROBE KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            116

TABLE 43              ACCESSORIES & OTHER CONSUMABLES MARKET, BY REGION,

2023–2030 (USD MILLION)            117

TABLE 44              NORTH AMERICA: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            117

TABLE 45              EUROPE: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            118

TABLE 46              ASIA PACIFIC: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            118

TABLE 47              LATIN AMERICA: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            119

TABLE 48              MIDDLE EAST: ACCESSORIES & OTHER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)                 119

TABLE 49              GCC COUNTRIES: ACCESSORIES & OTHER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            119

TABLE 50              IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            120

TABLE 51              NORTH AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            120

TABLE 52              EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            121

TABLE 53              ASIA PACIFIC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            121

TABLE 54              LATIN AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            122

TABLE 55              MIDDLE EAST: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION)                 122

TABLE 56              GCC COUNTRIES: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            122

TABLE 57              IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            123

TABLE 58              AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            124

TABLE 59              NORTH AMERICA: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       124

TABLE 60              EUROPE: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               125

TABLE 61              ASIA PACIFIC: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               125

TABLE 62              LATIN AMERICA: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 63              MIDDLE EAST: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY REGION, 2023–2030 (USD MILLION)   126

TABLE 64              GCC COUNTRIES: AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 65              MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            127

TABLE 66              NORTH AMERICA: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               128

TABLE 67              EUROPE: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            128

TABLE 68              ASIA PACIFIC: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               129

TABLE 69              LATIN AMERICA: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               129

TABLE 70              MIDDLE EAST: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY REGION, 2023–2030 (USD MILLION)   130

TABLE 71              GCC COUNTRIES: MANUAL IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               130

TABLE 72              IN SITU HYBRIDIZATION SOFTWARE MARKET, BY REGION,

2023–2030 (USD MILLION)            131

TABLE 73              NORTH AMERICA: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 131

TABLE 74              EUROPE: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 75              ASIA PACIFIC: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 76              LATIN AMERICA: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 133

TABLE 77              MIDDLE EAST: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY REGION,

2023–2030 (USD MILLION)            133

TABLE 78              GCC COUNTRIES: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 133

TABLE 79              IN SITU HYBRIDIZATION SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            134

TABLE 80              NORTH AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 134

TABLE 81              EUROPE: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 82              ASIA PACIFIC: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 83              LATIN AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            136

TABLE 84              MIDDLE EAST: IN SITU HYBRIDIZATION SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            136

TABLE 85              GCC COUNTRIES: IN SITU HYBRIDIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 86              IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)                137

TABLE 87              DATA INTERPRETATION SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            138

TABLE 88              NORTH AMERICA: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 138

TABLE 89              EUROPE: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            139

TABLE 90              ASIA PACIFIC: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            139

TABLE 91              LATIN AMERICA: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 92              MIDDLE EAST: DATA INTERPRETATION SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            140

TABLE 93              GCC COUNTRIES: DATA INTERPRETATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 94              CUSTOM PROBE DESIGN SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            141

TABLE 95              NORTH AMERICA: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 142

TABLE 96              EUROPE: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 97              ASIA PACIFIC: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            143

TABLE 98              LATIN AMERICA: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 143

TABLE 99              MIDDLE EAST: CUSTOM PROBE DESIGN SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            144

TABLE 100            GCC COUNTRES: CUSTOM PROBE DESIGN SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 144

TABLE 101            IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            146

TABLE 102            FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION,

2023–2030 (USD MILLION)            147

TABLE 103            NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               147

TABLE 104            EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            148

TABLE 105            ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               148

TABLE 106            LATIN AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               149

TABLE 107            MIDDLE EAST: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY REGION, 2023–2030 (USD MILLION)   149

TABLE 108            GCC COUNTRIES: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               149

TABLE 109            FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            150

TABLE 110            DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION)                 151

TABLE 111            NORTH AMERICA: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151

TABLE 112            EUROPE: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               152

TABLE 113            ASIA PACIFIC: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152

TABLE 114            LATIN AMERICA: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153

TABLE 115            MIDDLE EAST: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 153

TABLE 116            GCC COUNTRIES: DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153

TABLE 117            RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION)                 154

TABLE 118            NORTH AMERICA: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155

TABLE 119            EUROPE: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               155

TABLE 120            ASIA PACIFIC: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156

TABLE 121            LATIN AMERICA: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156

TABLE 122            MIDDLE EAST: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 157

TABLE 123            GCC COUNTRIES: RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157

TABLE 124            PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION)                 158

TABLE 125            NORTH AMERICA: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 158

TABLE 126            EUROPE: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               159

TABLE 127            ASIA PACIFIC: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159

TABLE 128            LATIN AMERICA: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160

TABLE 129            MIDDLE EAST: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY REGION, 2023–2030 (USD MILLION) 160

TABLE 130            GCC COUNTRIES: PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160

TABLE 131            CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY REGION,

2023–2030 (USD MILLION)            161

TABLE 132            NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 133            EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            162

TABLE 134            ASIA PACIFIC: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 135            LATIN AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 136            MIDDLE EAST: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET,

BY REGION, 2023–2030 (USD MILLION)   164

TABLE 137            GCC COUNTRIES: CHROMOGENIC IN SITU HYBRIDIZATION (CISH) MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               164

TABLE 138            IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              166

TABLE 139            IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   167

TABLE 140            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     167

TABLE 141            EUROPE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       168

TABLE 142            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     168

TABLE 143            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     169

TABLE 144            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)          169

TABLE 145            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     169

TABLE 146            IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         170

TABLE 147            CANCER DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)            171

TABLE 148            NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            171

TABLE 149            EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            172

TABLE 150            ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            172

TABLE 151            LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            173

TABLE 152            MIDDLE EAST: CANCER DIAGNOSTICS MARKET, BY REGION,

2023–2030 (USD MILLION)            173

TABLE 153            GCC COUNTRIES: CANCER DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            173

TABLE 154            INFECTIOUS DISEASE DIAGNOTICS MARKET, BY REGION,

2023–2030 (USD MILLION)            174

TABLE 155            NORTH AMERICA: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 175

TABLE 156            EUROPE: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            175

TABLE 157            ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            176

TABLE 158            LATIN AMERICA: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            176

TABLE 159            MIDDLE EAST: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY REGION,

2023–2030 (USD MILLION)            177

TABLE 160            GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 177

TABLE 161            GENETIC DISEASE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)          178

TABLE 162            NORTH AMERICA: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            178

TABLE 163            EUROPE: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            179

TABLE 164            ASIA PACIFIC: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            179

TABLE 165            LATIN AMERICA: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            180

TABLE 166            MIDDLE EAST: GENETIC DISEASE DIAGNOSTICS MARKET, BY REGION,

2023–2030 (USD MILLION)            180

TABLE 167            GCC COUNTRIES: GENETIC DISEASE DIAGNOSTICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            180

TABLE 168            OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            181

TABLE 169            NORTH AMERICA: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               181

TABLE 170            EUROPE: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            182

TABLE 171            ASIA PACIFIC: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            182

TABLE 172            LATIN AMERICA: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               183

TABLE 173            MIDDLE EAST: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)                 183

TABLE 174            GCC COUNTRIES: OTHER CLINCAL DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               183

TABLE 175            IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)            184

TABLE 176            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       184

TABLE 177            EUROPE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               185

TABLE 178            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               185

TABLE 179            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       186

TABLE 180            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   186

TABLE 181            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       186

TABLE 182            IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE,

2023–2030 (USD MILLION)            187

TABLE 183            NEUROSCIENCE RESEARCH MARKET, BY REGION, 2023–2030 (USD MILLION)          188

TABLE 184            NORTH AMERICA: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            188

TABLE 185            EUROPE: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            189

TABLE 186            ASIA PACIFIC: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            189

TABLE 187            LATIN AMERICA: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            190

TABLE 188            MIDDLE EAST: NEUROSCIENCE RESEARCH MARKET, BY REGION,

2023–2030 (USD MILLION)            190

TABLE 189            GCC COUNTRIES: NEUROSCIENCE RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            190

TABLE 190          IMMUNOLOGY RESEARCH MARKET, BY REGION, 2023–2030 (USD MILLION)            191

TABLE 191            NORTH AMERICA: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            192

TABLE 192            EUROPE: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            192

TABLE 193            ASIA PACIFIC: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            193

TABLE 194            LATIN AMERICA: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            193

TABLE 195            MIDDLE EAST: IMMUNOLOGY RESEARCH MARKET, BY REGION,

2023–2030 (USD MILLION)            194

TABLE 196            GCC COUNTRIES: IMMUNOLOGY RESEARCH MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            194

TABLE 197            OTHER RESEARCH APPLICATIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            195

TABLE 198            NORTH AMERICA: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            195

TABLE 199            EUROPE: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            196

TABLE 200            ASIA PACIFIC: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            196

TABLE 201            LATIN AMERICA: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            197

TABLE 202            MIDDLE EAST: OTHER RESEARCH APPLICATIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            197

TABLE 203            GCC COUNTRIES: OTHER RESEARCH APPLICATIONS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            197

TABLE 204            IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT,

BY REGION, 2023–2030 (USD MILLION)   198

TABLE 205            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)     199

TABLE 206            EUROPE: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 199

TABLE 207            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)     200

TABLE 208            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)     200

TABLE 209            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)            201

TABLE 210            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)     201

TABLE 211            IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION)                203

TABLE 212            IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)       204

TABLE 213            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     204

TABLE 214            EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)            205

TABLE 215            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     205

TABLE 216            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     206

TABLE 217            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)          206

TABLE 218            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     206

TABLE 219            IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 207

TABLE 220            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     207

TABLE 221            EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 208

TABLE 222            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     208

TABLE 223            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     209

TABLE 224            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)            209

TABLE 225            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     209

TABLE 226            IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          210

TABLE 227            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   211

TABLE 228            EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     211

TABLE 229            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   212

TABLE 230            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   212

TABLE 231            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)        213

TABLE 232            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   213

TABLE 233            IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,

BY REGION, 2023–2030 (USD MILLION)   214

TABLE 234            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     214

TABLE 235            EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       215

TABLE 236            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     215

TABLE 237            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     216

TABLE 238            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION)          216

TABLE 239            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     216

TABLE 240            IN SITU HYBRIDIZATION MARKET, BY REGION, 2023–2030 (USD MILLION)            218

TABLE 241            NORTH AMERICA: KEY MACROINDICATORS                 220

TABLE 242            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            221

TABLE 243            NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 221

TABLE 244            NORTH AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 222

TABLE 245            NORTH AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            222

TABLE 246            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            222

TABLE 247            NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY TYPE, 2023–2030 (USD MILLION)         223

TABLE 248            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            223

TABLE 249            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            224

TABLE 250            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 224

TABLE 251            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            225

TABLE 252            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            225

TABLE 253            US: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION)     226

TABLE 254            US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            226

TABLE 255            US: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            227

TABLE 256          US: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            227

TABLE 257            US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            227

TABLE 258            US: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            228

TABLE 259            US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            228

TABLE 260            US: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         229

TABLE 261            US: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 229

TABLE 262            US: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION)                230

TABLE 263            CANADA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            231

TABLE 264            CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            231

TABLE 265            CANADA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            232

TABLE 266            CANADA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            232

TABLE 267            CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            232

TABLE 268            CANADA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            233

TABLE 269            CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            233

TABLE 270            CANADA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 234

TABLE 271            CANADA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         234

TABLE 272            CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            235

TABLE 273            EUROPE: KEY MACROINDICATORS          236

TABLE 274            EUROPE: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            237

TABLE 275            EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            237

TABLE 276            EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            238

TABLE 277            EUROPE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            238

TABLE 278            EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            238

TABLE 279            EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            239

TABLE 280            EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            239

TABLE 281            EUROPE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 240

TABLE 282            EUROPE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         240

TABLE 283            EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            241

TABLE 284            EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            241

TABLE 285            GERMANY: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            242

TABLE 286            GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            242

TABLE 287            GERMANY: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            243

TABLE 288            GERMANY: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            243

TABLE 289            GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            243

TABLE 290            GERMANY: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            244

TABLE 291            GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            244

TABLE 292            GERMANY: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 245

TABLE 293            GERMANY: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         245

TABLE 294            GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            246

TABLE 295            UK: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION)     247

TABLE 296            UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            247

TABLE 297            UK: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            247

TABLE 298          UK: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            248

TABLE 299            UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            248

TABLE 300            UK: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            248

TABLE 301            UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            249

TABLE 302            UK: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 249

TABLE 303            UK: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 250

TABLE 304            UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION)                250

TABLE 305            FRANCE: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            251

TABLE 306            FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            251

TABLE 307            FRANCE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            252

TABLE 308            FRANCE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            252

TABLE 309            FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            252

TABLE 310            FRANCE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            253

TABLE 311            FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            253

TABLE 312            FRANCE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 254

TABLE 313            FRANCE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         254

TABLE 314            FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            255

TABLE 315            ITALY: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION)     256

TABLE 316            ITALY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            256

TABLE 317            ITALY: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            257

TABLE 318            ITALY: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            257

TABLE 319            ITALY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            257

TABLE 320            ITALY: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            258

TABLE 321            ITALY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            258

TABLE 322            ITALY: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 259

TABLE 323            ITALY: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 259

TABLE 324            ITALY: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            260

TABLE 325            SPAIN: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            261

TABLE 326            SPAIN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            261

TABLE 327            SPAIN: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            261

TABLE 328            SPAIN: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            262

TABLE 329            SPAIN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            262

TABLE 330            SPAIN: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            262

TABLE 331            SPAIN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            263

TABLE 332            SPAIN: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 263

TABLE 333            SPAIN: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 264

TABLE 334            SPAIN: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            264

TABLE 335            REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            265

TABLE 336            REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 265

TABLE 337            REST OF EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 266

TABLE 338            REST OF EUROPE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            266

TABLE 339            REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            266

TABLE 340            REST OF EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY TYPE, 2023–2030 (USD MILLION)         267

TABLE 341            REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            267

TABLE 342            REST OF EUROPE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            268

TABLE 343            REST OF EUROPE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268

TABLE 344            REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            269

TABLE 345            ASIA PACIFIC: KEY MACROINDICATORS                 271

TABLE 346            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            271

TABLE 347            ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            272

TABLE 348            ASIA PACIFIC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            272

TABLE 349            ASIA PACIFIC: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            272

TABLE 350            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            273

TABLE 351            ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            273

TABLE 352            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            274

TABLE 353            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            274

TABLE 354            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         275

TABLE 355            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            275

TABLE 356            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            276

TABLE 357            CHINA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            277

TABLE 358            CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            277

TABLE 359            CHINA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            277

TABLE 360            CHINA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            278

TABLE 361            CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            278

TABLE 362            CHINA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            278

TABLE 363            CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            279

TABLE 364            CHINA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 279

TABLE 365            CHINA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 280

TABLE 366            CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            280

TABLE 367            JAPAN: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            281

TABLE 368            JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            281

TABLE 369            JAPAN: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            282

TABLE 370            JAPAN: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            282

TABLE 371            JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            282

TABLE 372            JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            283

TABLE 373            JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            283

TABLE 374            JAPAN: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 284

TABLE 375            JAPAN: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 284

TABLE 376            JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            285

TABLE 377            INDIA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            286

TABLE 378            INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            286

TABLE 379            INDIA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            287

TABLE 380            INDIA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            287

TABLE 381            INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            287

TABLE 382            INDIA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            288

TABLE 383            INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            288

TABLE 384            INDIA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 289

TABLE 385            INDIA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 289

TABLE 386            INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            290

TABLE 387            AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            291

TABLE 388            AUSTRALIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 389            AUSTRALIA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 390            AUSTRALIA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            292

TABLE 391            AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            292

TABLE 392            AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            293

TABLE 393            AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            293

TABLE 394            AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 294

TABLE 395            AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         294

TABLE 396            AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            295

TABLE 397            SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            296

TABLE 398            SOUTH KOREA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            296

TABLE 399            SOUTH KOREA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            297

TABLE 400            SOUTH KOREA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            297

TABLE 401            SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            297

TABLE 402            SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            298

TABLE 403            SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            298

TABLE 404            SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            299

TABLE 405            SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299

TABLE 406            SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            300

TABLE 407            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            301

TABLE 408            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 301

TABLE 409            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 302

TABLE 410            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 302

TABLE 411            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            302

TABLE 412            REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            303

TABLE 413            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            303

TABLE 414            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            304

TABLE 415            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 304

TABLE 416            REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            305

TABLE 417            LATIN AMERICA: KEY MACROINDICATORS                 306

TABLE 418            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            307

TABLE 419            LATIN AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 307

TABLE 420            LATIN AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            308

TABLE 421            LATIN AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            308

TABLE 422            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            308

TABLE 423            LATIN AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            309

TABLE 424            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            309

TABLE 425            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            310

TABLE 426            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 310

TABLE 427            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            311

TABLE 428            LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            311

TABLE 429            BRAZIL: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            312

TABLE 430            BRAZIL: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            312

TABLE 431            BRAZIL: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            313

TABLE 432            BRAZIL: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            313

TABLE 433            BRAZIL: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            313

TABLE 434            BRAZIL: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            314

TABLE 435            BRAZIL: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            314

TABLE 436            BRAZIL: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 315

TABLE 437            BRAZIL: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 315

TABLE 438            BRAZIL: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            316

TABLE 439            MEXICO: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            317

TABLE 440            MEXICO: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            317

TABLE 441            MEXICO: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            317

TABLE 442            MEXICO: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            318

TABLE 443            MEXICO: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            318

TABLE 444            MEXICO: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            318

TABLE 445            MEXICO: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            319

TABLE 446            MEXICO: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 319

TABLE 447            MEXICO: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         320

TABLE 448            MEXICO: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            320

TABLE 449            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            321

TABLE 450            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         321

TABLE 451            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         322

TABLE 452            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            322

TABLE 453            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            322

TABLE 454            REST OF LATIN AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            323

TABLE 455            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            323

TABLE 456            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)        324

TABLE 457            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                324

TABLE 458            REST OF LATIN AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            325

TABLE 459            MIDDLE EAST: KEY MACROINDICATORS                 326

TABLE 460            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            326

TABLE 461            MIDDLE EAST: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            327

TABLE 462            MIDDLE EAST: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            327

TABLE 463            MIDDLE EAST: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            327

TABLE 464            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            328

TABLE 465            MIDDLE EAST: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            328

TABLE 466            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            329

TABLE 467            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            329

TABLE 468            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         330

TABLE 469            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            330

TABLE 470            MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY REGION,

2023–2030 (USD MILLION)            330

TABLE 471            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            331

TABLE 472            GCC COUNTRIES: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 331

TABLE 473            GCC COUNTRIES: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 332

TABLE 474            GCC COUNTRIES: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            332

TABLE 475            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            332

TABLE 476            GCC COUNTRIES: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET,

BY TYPE, 2023–2030 (USD MILLION)         333

TABLE 477            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            333

TABLE 478            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            334

TABLE 479            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 334

TABLE 480            GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            335

TABLE 481            GCC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     335

TABLE 482            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION)            336

TABLE 483            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         336

TABLE 484            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         337

TABLE 485            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            337

TABLE 486            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            337

TABLE 487            KINGDOM OF SAUDI ARABIA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION) 338

TABLE 488            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            338

TABLE 489            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)        339

TABLE 490            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                339

TABLE 491            KINGDOM OF SAUDI ARABIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION)            340

TABLE 492            UAE: IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2023–2030 (USD MILLION)     341

TABLE 493            UAE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            341

TABLE 494            UAE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            342

TABLE 495            UAE: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            342

TABLE 496            UAE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            342

TABLE 497            UAE: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            343

TABLE 498            UAE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            343

TABLE 499            UAE: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 344

TABLE 500            UAE: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 344

TABLE 501            UAE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2023–2030 (USD MILLION)                345

TABLE 502            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            346

TABLE 503            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION CONSUMABLES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         346

TABLE 504            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION INSTRUMENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         347

TABLE 505            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            347

TABLE 506            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            347

TABLE 507            REST OF GCC COUNTRIES: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            348

TABLE 508            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            348

TABLE 509            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)        349

TABLE 510            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                349

TABLE 511            REST OF GCC COUNTRIES: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            350

TABLE 512            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            351

TABLE 513            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 351

TABLE 514            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 352

TABLE 515            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            352

TABLE 516            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            352

TABLE 517            REST OF MIDDLE EAST: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2023–2030 (USD MILLION)            353

TABLE 518            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            353

TABLE 519            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)        354

TABLE 520            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                354

TABLE 521            REST OF MIDDLE EAST: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            355

TABLE 522            AFRICA: KEY MACROINDICATORS            356

TABLE 523            AFRICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING,

2023–2030 (USD MILLION)            356

TABLE 524            AFRICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,

2023–2030 (USD MILLION)            357

TABLE 525            AFRICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            357

TABLE 526            AFRICA: IN SITU HYBRIDIZATION SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            357

TABLE 527            AFRICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            358

TABLE 528            AFRICA: FLUORESCENCE IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE,

2023–2030 (USD MILLION)            358

TABLE 529            AFRICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            358

TABLE 530            AFRICA: IN SITU HYBRIDIZATION MARKET FOR CLINICAL DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 359

TABLE 531            AFRICA: IN SITU HYBRIDIZATION MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 359

TABLE 532            AFRICA: IN SITU HYBRIDIZATION MARKET, BY END USER,

2023–2030 (USD MILLION)            360

TABLE 533            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET  361

TABLE 534            IN SITU HYBRIDIZATION MARKET: DEGREE OF COMPETITION 365

TABLE 535            IN SITU HYBRIDIZATION MARKET: REGION FOOTPRINT       370

TABLE 536            IN SITU HYBRIDIZATION MARKET: OFFERING FOOTPRINT       371

TABLE 537            IN SITU HYBRIDIZATION MARKET: TECHNOLOGY FOOTPRINT        372

TABLE 538            IN SITU HYBRIDIZATION MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS  375

TABLE 539            IN SITU HYBRIDIZATIONN MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY OFFERING AND REGION    376

TABLE 540            IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025       379

TABLE 541            IN SITU HYBRIDIZATION MARKET: DEALS, JANUARY 2022–JUNE 2025              380

TABLE 542            F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW          381

TABLE 543            F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    382

TABLE 544            F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025       384

TABLE 545            DANAHER: COMPANY OVERVIEW            386

TABLE 546            DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED             387

TABLE 547            DANAHER: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025  389

TABLE 548            DANAHER: DEALS, JANUARY 2022–JUNE 2025                 390

TABLE 549            ABBOTT: COMPANY OVERVIEW                392

TABLE 550            ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED             393

TABLE 551            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          399

TABLE 552            THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    400

TABLE 553            BIO-TECHNE: COMPANY OVERVIEW      402

TABLE 554            BIO-TECHNE: PRODUCTS/SERVICES/SOLUTIONS OFFERED    403

TABLE 555            BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025  405

TABLE 556            BIO-TECHNE: DEALS, JANUARY 2022–JUNE 2025                 406

TABLE 557            AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW          408

TABLE 558            AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    409

TABLE 559            QIAGEN: COMPANY OVERVIEW 412

TABLE 560            QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED             414

TABLE 561            BIOCARE MEDICAL, LLC: COMPANY OVERVIEW                 415

TABLE 562            BIOCARE MEDICAL, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED    415

TABLE 563            BIOCARE MEDICAL, LLC: DEALS, JANUARY 2022–JUNE 2025             419

TABLE 564            BIOVIEW: COMPANY OVERVIEW               421

TABLE 565            BIOVIEW: PRODUCTS/SERVICES/SOLUTIONS OFFERED             421

TABLE 566            CREATIVE BIOARRAY: COMPANY OVERVIEW                 422

TABLE 567            CREATIVE BIOARRAY: PRODUCTS/SERVICES/SOLUTIONS OFFERED    422

TABLE 568            ABNOVA CORPORATION: COMPANY OVERVIEW                 425

TABLE 569            ABNOVA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    425

TABLE 570            ZYTOMICS: COMPANY OVERVIEW           427

TABLE 571            ZYTOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED             427

TABLE 572            ENZO BIOCHEM INC.: COMPANY OVERVIEW                 431

TABLE 573            ENZO BIOCHEM INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    432

TABLE 574            ENZO BIOCHEM INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025              434

TABLE 575            CYTOTEST INC.: COMPANY OVERVIEW 435

TABLE 576            CYTOTEST INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    435

TABLE 577            GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW   438

TABLE 578            GENEMED BIOTECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    438

TABLE 579            MOLECULAR INSTRUMENTS, INC.: COMPANY OVERVIEW          440

TABLE 580            OXFORD GENE TECHNOLOGY IP LIMITED: COMPANY OVERVIEW   441

TABLE 581            HISTO-LINE LABORATORIES: COMPANY OVERVIEW          442

TABLE 582            METASYSTEMS: COMPANY OVERVIEW  443

TABLE 583            BIOGENEX: COMPANY OVERVIEW           445

TABLE 584            LGC BIORESEARCH TECHNOLOGIES: COMPANY OVERVIEW          446

TABLE 585            BIODISCOVERY LLC: COMPANY OVERVIEW                 447

TABLE 586            KANEKA EUROGENTEC S.A.: COMPANY OVERVIEW          448

TABLE 587            LIFE TECHNOLOGIES (INDIA) PVT. LTD.: COMPANY OVERVIEW   449

TABLE 588            GENECOPOEIA, INC.: COMPANY OVERVIEW                 450

LIST OF FIGURES

FIGURE 1              IN SITU HYBRIDIZATION MARKET SEGMENTATION & REGIONAL SCOPE    41

FIGURE 2              IN SITU HYBRIDIZATION MARKET: YEARS CONSIDERED    43

FIGURE 3              IN SITU HYBRIDIZATION MARKET: RESEARCH DESIGN                45

FIGURE 4              IN SITU HYBRIDIZATION MARKET: BREAKDOWN OF PRIMARIES

(SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 47

FIGURE 5              IN SITU HYBRIDIZATION MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024      48

FIGURE 6              GLOBAL MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS

(BOTTOM-UP APPROACH), 2024                49

FIGURE 7              IN SITU HYBRIDIZATION MARKET: REVENUE ANALYSIS OF HOFFMANN-LA ROCHE LTD. (2024)             49

FIGURE 8              IN SITU HYBRIDIZATION MARKET SIZE VALIDATION FROM PRIMARY SOURCES                51

FIGURE 9              SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH          51

FIGURE 10            IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS (2025–2030)            53

FIGURE 11            IN SITU HYBRIDIZATION MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS           54

FIGURE 12            IN SITU HYBRIDIZATION MARKET: DATA TRIANGULATION METHODOLOGY         55

FIGURE 13            IN SITU HYBRIDIZATION MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)               58

FIGURE 14            IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)      59

FIGURE 15            IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)       60

FIGURE 16            IN SITU HYBRIDIZATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)         61

FIGURE 17            REGIONAL ANALYSIS OF IN SITU HYBRIDIZATION MARKET            62

FIGURE 18            INCREASING ADOPTION OF IN SITU HYBRIDIZATION TECHNOLOGIES IN LABORATOY-DEVELOPED TESTS TO DRIVE MARKET            63

FIGURE 19            US AND CONSUMABLES ACCOUNTED FOR LARGEST NORTH AMERICAN MARKET SHARE IN 2024    64

FIGURE 20            HOSPITALS & DIAGNOSTIC LABORATORIES TO COMMAND LARGEST END USER MARKET SHARE IN 2024                 65

FIGURE 21            CHINA TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD               66

FIGURE 22            IN SITU HYBRIDIZATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES         67

FIGURE 23            IN SITU HYBRIDIZATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS                 73

FIGURE 24            IN SITU HYBRIDIZATION PRODUCTS MARKET: VALUE CHAIN ANALYSIS               74

FIGURE 25            IN SITU HYBRIDIZATION MARKET: ECOSYSTEM ANALYSIS            76

FIGURE 26            TOP APPLICANTS/OWNERS (COMPANIES) FOR IN SITU HYBRIDIZATION PATENTS         80

FIGURE 27            IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS 84

FIGURE 28            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION-BASED OFFERINGS        86

FIGURE 29            KEY BUYING CRITERIA, BY END USER    87

FIGURE 30            IMPACT OF AI ON IN SITU HYBRIDIZATION ECOSYSTEM       96

FIGURE 31            NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT       219

FIGURE 32            ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT       270

FIGURE 33            REVENUE ANALYSIS OF KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET,

2020–2024 (USD MILLION)            363

FIGURE 34            MARKET SHARE ANALYSIS OF KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET (2024)               364

FIGURE 35            IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       368

FIGURE 36            IN SITU HYBRIDIZATION MARKET: COMPANY FOOTPRINT       369

FIGURE 37            IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 374

FIGURE 38            EV/EBITDA OF KEY VENDORS   377

FIGURE 39            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                377

FIGURE 40            BRAND/PRODUCT COMPARATIVE ANALYSIS OF IN SITU HYBRIDIZATION-BASED ASSAYS              378

FIGURE 41            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT          382

FIGURE 42            DANAHER: COMPANY SNAPSHOT            387

FIGURE 43            ABBOTT: COMPANY SNAPSHOT                393

FIGURE 44            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT          400

FIGURE 45            BIO-TECHNE: COMPANY SNAPSHOT      403

FIGURE 46            AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT          409

FIGURE 47            QIAGEN: COMPANY SNAPSHOT                 413

FIGURE 48            ENZO BIOCHEM INC.: COMPANY SNAPSHOT                 432

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧